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Background: Fibroblast Growth Factor (FGF) 23 influences endothelial integrity and few reports have studied the
association between FGF23 and Kawasaki syndrome (KS), a childhood vasculitis displaying a high risk of subsequent
cardiac abnormalities (CaA).
Aim: To investigate the genetic variation in the FGF23 gene in a cohort of KS children and its association with
serum FGF23 levels and eventual development of CaA, including both coronary artery dilatations and aneurysms.
Patients and methods: 84 Italian KS children were recruited; 24/84 (28.6%) developed CaA. Each patient
underwent evaluation of serum FGF23 levels and FGF23 genotype: the frequency of the c.212-37insC (rs3832879)
polymorphism in intron 1 was examined and compared with sex, age at disease onset, fever duration, laboratory
data, and occurrence of CaA. Univariate statistical analysis of categorical parameters was performed by the Pearson’s
Chi-square test or Fisher’s exact test as appropriate. Parametric variables were assessed by Student’s t-test for un-
paired data. Independent predictors of disease were studied by a logistic regression model.
Results: 28/84 patients carried the FGF23 polymorphism (33.3%) and had higher serum FGF23 levels (p < 0.01).
FGF23 polymorphism was significantly associated with CaA compared to wild type FGF23 children (respectively,
p = 0.03 and p = 0.05). The comparison with demographical, clinical or laboratory data was not significant.
Conclusions: The prevalent segregation of the c.212-37insC polymorphism in children with CaA advocates a
possible functional FGF23 role in the predisposition to higher serum levels of FGF23 and potential occurrence of
any coronary artery abnormalities in KS.
Keywords: Kawasaki syndrome, Fibroblast growth factor 23, Cardiac abnormalities, ChildKawasaki syndrome (KS), a systemic panvasculitis of un-
known origin affecting all medium/small-sized vessels,
typically occurring in early childhood, bears an outstand-
ing risk of cardiac abnormalities (CaA), ranging from
asymptomatic coronary artery ectasia to giant aneurysms
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stated.during the subacute phase of KS, and an increasing body
of evidence supports a widespread vascular dysfunction
in KS with risk of atherogenesis during adulthood of
these patients [2].
The discovery of fibroblast growth factor 23 (FGF23),
a bone-derived hormone that regulates systemic phos-
phate homeostasis and vitamin D metabolism via FGF-
receptor 1 (FGFr1)/cofactor Klotho, which is included in
a previously unrecognized hormonal bone-parathyroid-
kidney axis [3], has uncovered new implications for
skeletal fragility, renal disease-associated morbidity, and
even cardiovascular pathology [4].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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variation in the FGF23 gene in a cohort of children with
a confirmed diagnosis of KS and its association with
serum FGF23 levels and development of CaA.
Patients and methods
Our study population included 84 consecutive children of
Italian ancestry, 62 males and 22 females, with a mean age
of 40.8 months, who fulfilled the American Heart Associ-
ation criteria for the diagnosis of KS. Every patient was
treated with intravenous immunoglobulin (IVIG, 2 g/kg
over 10–12 hours within the 10th day since disease onset)
and aspirin (50–80 mg/kg/day in 4 doses during the acute
phase). All patients were immunoglobulin-responsive, and
no repeated cycles of IVIG were required. No additional
therapies were adopted. Fever duration (in days) was re-
corded for each patient. Endocrinological and chronic renal
diseases, which can be associated with inappropriately high
serum FGF23 levels or phosphate wasting and impaired
bone mineralization, were excluded in all patients. Each
patient underwent evaluation of serum FGF23 levels
(expressed in pg/ml and measured by an ELISA assay,
Immunotopics Inc. San Clemente, CA, USA; lower limit of
detection: 1.0 pg/ml) at the time of inclusion in the study
(i.e. when diagnosis of KS was formulated), in combination
with the assessment of different laboratory data: erythrose-
dimentation rate (ESR), C-reactive protein (CRP), haemo-
globin (Hb), platelet count, fibrinogen, total cholesterol,
HDL cholesterol, LDL cholesterol, and triglycerids. All
patients underwent 2D-echocardiogram at admission
and routinely, if coronary artery involvement was ab-
sent. Twenty-four/84 KS patients (28.6%) developed
CaA in terms of coronary artery complications (14 pa-
tients had coronary aneurysms and/or dilatations of
whatever dimensions) and pericardial effusion (in 10
patients): all these children were more closely con-
trolled by 2D-echocardiograms, performed always by
the same pediatric cardiologist.
Fibroblast growth factor 23 gene evaluation
Both ethical approval from the Ethics Committee of the
University of Florence and a formal informed consent by
relatives or tutors of each child were obtained. Patients’
DNA was extracted from peripheral blood mononuclear
cells. The three FGF23 exons, including the intron-exon
boundary regions, were PCR-amplified and analyzed on
ABI Prism 3100 Genetic Analyzer (Applied Biosystems,
Foster City, CA). Primer sequences were as follows: exon
1for GGGGTCTTTGCACTTTCTTTC; exon 1rev GGTT
GGATTAGCCCTCCAGT; exon 2for ATCAATCCAGG
GAGGTTTCA; exon 2rev GGAAACAGGTCACCAGG
GTA; exon 3for AGGAGGAGCTGGGGAGTG and exon
3rev GACCTGGTCCTTGGGAAGA. PCR was performed
with 1.5 mM magnesium chloride, 0.2 mM deoxynucleotidetriphosphates, 0.2 μM of each primer, 1 U of Taq poly-
merase and 100 ng of genomic DNA as template. The
obtained sequences were compared with the wild type
reference sequence of the gene, published on Genbank
Database (NT-009759). FGF23 gene analysis revealed
the polymorphism c.212-37insC in intron 1, character-
ized by a C insertion in the intronic region between −36
and −37 nucleotide (rs3832879: NM_020638.2:c.212-
37_212-36insC), in a subset of KS patients. Subjects
without this FGF23 polymorphism were indicated as
wild type.
Statistical analysis
Univariate statistical analysis of categorical parameters
was performed by the Pearson’s Chi-square test or Fish-
er’s exact test as appropriate. Parametric variables were
assessed by Student’s t-test for unpaired data. The com-
parison of age of onset between the two groups was per-
formed by Mann–Whitney U test. Variables significantly
associated with CaA at the univariate analysis were en-
tered into a logistic regression model to identify inde-
pendent predictors of disease. Values were expressed as
total count [% ratio] for categorical variables, means ±
SD for parametric variables and value [95% Confidence
Interval] for Odds ratio. Age of onset was expressed as
median [quartiles]. A p value of 0.05 or less was consid-
ered as significant.
Results
Twenty-eight patients with KS carried the FGF23 c.212-
37insC polymorphism (33.3%). We found that male sex
was significantly associated with the polymorphism (91.7%
vs 61.7%, p = 0.03). Patients presenting the FGF23 poly-
morphism had also significantly higher serum FGF23
levels (41.4 pg/ml ± 53.9 vs 10.7 pg/ml ± 13.5, p < 0.01). In
addition, the FGF23 polymorphism was significantly associ-
ated with CaA: indeed, patients presenting with coronary
dilatations or aneurysms were significantly more repre-
sented in the subgroup with FGF23 polymorphism,
compared to wild type FGF23 children (29.2% vs 11.7%,
p = 0.05). The number of patients with only coronary aneu-
rysms (3 patients) was too small to obtain statistical
significance in a separate subgroup analysis. Neither peri-
cardial effusion, nor the overall signs of cardiac involvement
(in the whole) were significantly associated with the FGF23
polymorphism. No demographical, clinical or labora-
tory data were found to be associated with the FGF23
polymorphism.
At the multivariate analysis, FGF23 polymorphism was
independently associated with both CaA and high serum
FGF23 levels (respectively Odds ratios: 4.3 [1.1-16.2],
p = 0.03 and 1.05 [1.0-1.1], p = 0.01). Male sex, that
showed a strong univariate association with the FGF23
polymorphism, did not reach a statistical significance at
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morphism was mostly observed in males (22 out of 24,
91.7%), we probably have not sufficient data to deter-
mine its real impact in the male sex (see Table 1).
Discussion
Endothelium dysfunction is an established trigger for
cardiovascular accidents in the general population and is
a major pathogenetic mechanism involved in KS [5].
FGF23, which is part of hormonal bone-parathyroid-
kidney axis, modulated by parathyroid hormone, 1,25
(OH)2-vitamin D, diet and serum phosphorus levels, ex-
erts its bioactivity on selected target-tissues interacting
with its receptor FGFr, largely diffuse in bone tissue and
different endothelia, in the presence of Klotho co-factor
[6]. Elevated serum levels of FGF23 have been demon-
strated in children with rickets and diminished bone
mineral density, but also a direct FGF23 effect has been
hypothesized on the heart [7,8]. In a previous study weTable 1 Univariate statistical analysis with demographic/labo
with the FGF23 gene polymorphism in the cohort of 84 child
Variable FGF23 wild gene
Sex (M/F) 40/20
(66.7%-33.3%)
Age of onset (in months) 24.5 [13.2-49.5]
Fever duration (in days) 8.7 ± 4.0
Laboratory data
Serum FGF23 10.7 ± 13.5
ESR at onset (mm/1 h) 83.3 ± 22.7
CRP at onset (mg/L) 14.0 ± 15.8
Hb at onset (g/L) 10.6 ± 1.1
Platelet count at onset (×109/L) 450.8 ± 142.1
Fibrinogen at onset (mg/dl) 672.33 ± 216.6
Total cholesterol (mg/dl) 162.2 ± 34.0
HDL cholesterol (mg/dl) 39.5 ± 14.6
LDL cholesterol (mg/dl) 103.7 ± 39.7
Triglycerides (mg/dl) 86.5 ± 58.1
Cardiac abnormalities
Coronary dilatations 6/54
(present/absent) (10.0%/90.0%)
Coronary aneurysms 2/58
(present/absent) (3.3%/96.7%)
Coronary aneurysms or dilatations 7/53
(present/absent) (11.7%/88.3%)
Pericardial effusion 7/53
(present/absent) (11.7%/88.3%)
Any cardiac involvement 14/46
(present/absent) (23.3%/76.7%)
All parametric data are expressed as mean ± SD. Age of onset is expressed as medihave observed that intact serum FGF23 levels in children
with KS were significantly higher when compared with
healthy controls, in particular those displaying CaA, re-
vealing the potential role of FGF23 as a marker suggest-
ive of cardiac complications [9]. Unfortunately there are
no other published studies on the association between
vasculitides in childhood and FGF23, and clinical trials
are needed to determine whether FGF23 is a modifiable
risk factor.
In this study we have investigated the genetic variation
in the FGF23 gene in a cohort of 84 children with KS
and its correlation with serum FGF23 levels and devel-
opment of CaA: we have found a significant correlation
between the FGF23 rs3832879 variant (which can be
found in 15.6% of the population; http://www.ncbi.nlm.
nih.gov/snp/?term=rs3832879) and both serum FGF23
levels and CaA, including both coronary artery dilata-
tions and aneurysms. In particular, patients with the
FGF23 polymorphism had higher serum FGF23 levelsratory variables and cardiac abnormalities in comparison
ren with Kawasaki syndrome recruited for this study
FGF23 polymorphism p value
22/2 0.03
(91.7%-8.3%)
36 [16.7-58.0] 0.39
9.3 ± 3.8 0.75
41.4 ± 53.9 0.01
83.5 ± 19.4 0.44
17.3 ± 16.9 0.52
10.2 ± 0.9 0.48
433.0 ± 124.1 0.86
732.6 ± 162.3 0.27
171.8 ± 22.3 0.13
39.6 ± 12.5 0.59
105.6 ± 29.6 0.44
89.7 ± 76.4 0.65
7/17 0.03
(29.2%/70.8%)
1/23 0.64
(4.2%/95.8%)
7/17 0.05
(29.2%/70.8%)
4/20 0.54
(16.7%/83.3%)
10/14 0.09
(41.7%/58.3%)
an [quartiles]. Categorical variables are expressed as raw numbers (%).
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tery dilatations or aneurysms (p = 0.05). Finally, the
multivariate analysis showed that both CaA and serum
FGF23 were independently associated with the FGF23
polymorphism (respectively p = 0.03 and p = 0.01).
In summary, coronary artery dilatations were demon-
strated in 29.2% of children bearing the FGF23 poly-
morphism and only in 10% of wild type FGF23 patients:
this striking difference might support the functional role
that this polymorphism could display on the susceptibil-
ity to CaA, although the details of the interaction of
FGF23 gene with other genetic systems remain unclear
at present.
From these preliminary results, which need to be repli-
cated on larger samples of patients, the segregation of
the FGF23 polymorphism in children with KS who de-
veloped CaA suggests its potential contribution to the
development of cardiovascular complications. Whether
this genotype may act in synergy with other genes or
specific environmental factors remains to be elucidated
in further studies.
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